COMPANY
Aeromics
Aeromics, Inc is a clinical-stage pharmaceutical company developing an intravenously administered aquaporin-4 (AQP4) inhibitor (AER-271) for severe, acute ischemic stroke that will prevent or arrest brain swelling (cerebral edema) following an ischemic event. From company website Source · Oct 12, 2026
Timeline
- Trial start 1: Phase 1 Study to Assess AER-271 source ↗
Clinical trials (lead sponsor) 1
| Record | Title | Phase | Status | Start | Primary completion |
|---|---|---|---|---|---|
| NCT03804476 | Phase 1 Study to Assess AER-271 | 1 | Completed | Jun 26, 2018 | Jul 18, 2019 (actual) |
NIH awards 6
- NIH award 5R44NS060199-05 FY2012: $745,127 awarded for that fiscal year; activity R44 (SBIR); PI PELLETIER, MARC F; recipient as written: AEROMICS, INC, New Haven, CT. Refinement of lead compounds to modulate water p source ↗
- NIH award 1R43NS074890-01A1 FY2011: $492,050 awarded for that fiscal year; activity R43 (SBIR); PI PELLETIER, MARC F; recipient as written: AEROMICS, INC, New Haven, CT. Scale-Up from Pilot To High-Throughput Screen source ↗
- NIH award 5R44NS060199-04 FY2011: $749,969 awarded for that fiscal year; activity R44 (SBIR); PI PELLETIER, MARC F; recipient as written: AEROMICS, INC, New Haven, CT. Refinement of lead compounds to modulate water p source ↗
- NIH award 2R44NS060199-03A1 FY2010: $754,297 awarded for that fiscal year; activity R44 (SBIR); PI PELLETIER, MARC F; recipient as written: AEROMICS, INC, New Haven, CT. Refinement of lead compounds to modulate water source ↗
- NIH award 5R43NS060199-02 FY2009: $300,000 awarded for that fiscal year; activity R43 (SBIR); PI PELLETIER, MARC F; recipient as written: AEROMICS, INC, New Haven, CT. Development of a high-throughput screen for inhi source ↗
- NIH award 1R43NS060199-01 FY2008: $300,000 awarded for that fiscal year; activity R43 (SBIR); PI PELLETIER, MARC F; recipient as written: AEROMICS, INC, New Haven, CT. Development of a high-throughput screen for inhi source ↗